Next Article in Journal
Germline Missense Variants in BRCA1: New Trends and Challenges for Clinical Annotation
Next Article in Special Issue
A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
Previous Article in Journal
Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer
Previous Article in Special Issue
Immunology of Plasmacytoid Dendritic Cells in Solid Tumors: A Brief Review
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview

Dendritic Cells and Cancer: From Biology to Therapeutic Intervention

1
Phylogica, Harry Perkins Institute, QEII Medical Centre, Nedlands, WA 6009, Australia
2
Department of Biochemistry and Molecular Biology, The University of Melbourne, Bio21, Molecular Science and Biotechnology Institute, Parkville, VIC 3010, Australia
3
Telethon Kids Institute, University of Western Australia, Northern Entrance, Perth Children’s Hospital, Nedlands, WA 6009, Australia
*
Author to whom correspondence should be addressed.
Joint first author.
Co-senior author.
Cancers 2019, 11(4), 521; https://doi.org/10.3390/cancers11040521
Received: 8 March 2019 / Revised: 5 April 2019 / Accepted: 7 April 2019 / Published: 11 April 2019
(This article belongs to the Special Issue Tumour Associated Dendritic Cells)
  |  
PDF [3175 KB, uploaded 23 April 2019]
  |  

Abstract

Inducing effective anti-tumor immunity has become a major therapeutic strategy against cancer. Dendritic cells (DC) are a heterogenous population of antigen presenting cells that infiltrate tumors. While DC play a critical role in the priming and maintenance of local immunity, their functions are often diminished, or suppressed, by factors encountered in the tumor microenvironment. Furthermore, DC populations with immunosuppressive activities are also recruited to tumors, limiting T cell infiltration and promoting tumor growth. Anti-cancer therapies can impact the function of tumor-associated DC and/or alter their phenotype. Therefore, the design of effective anti-cancer therapies for clinical translation should consider how best to boost tumor-associated DC function to drive anti-tumor immunity. In this review, we discuss the different subsets of tumor-infiltrating DC and their role in anti-tumor immunity. Moreover, we describe strategies to enhance DC function within tumors and harness these cells for effective tumor immunotherapy. View Full-Text
Keywords: tumor-associated dendritic cells; DC-based therapy; immunotherapy; checkpoint blockade; immunosuppression; novel therapies; cancer tumor-associated dendritic cells; DC-based therapy; immunotherapy; checkpoint blockade; immunosuppression; novel therapies; cancer
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Wylie, B.; Macri, C.; Mintern, J.D.; Waithman, J. Dendritic Cells and Cancer: From Biology to Therapeutic Intervention. Cancers 2019, 11, 521.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top